Author

Hongji Li

Observed name: H. Li

Institution: Jilin City Central Hospital

Observed institutions: Chinese PLA General Hospital, Jilin City Central Hospital

ORCID: 0009-0004-3883-4892

Observed ORCIDs: 0009-0004-3883-4892, 0009-0002-8176-2420

OpenAlex ID: A5041135095

First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report

2025 · Zaiyong Jin, Fei Zhou, et al. · Cancer Reports · 2

Neoadjuvant biosimilar trastuzumab/pertuzumab in HER2-positive breast cancer

2026 · Hongji Li, Ying Han · Asian Journal of Surgery

980P Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh B liver function: A prospective study

2024 · H. Li, X. Zhang, et al. · Annals of Oncology

UP-3.006: Association of Low Expression of Notch-1 and Jagged-1 in Human Papillary Bladder Cancer and Shorter Survival

2009 · T. Shi, X. Ma, et al. · Urology

Works count: 4

Citation count: 2

H-index: 1

I10-index: